Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valchlor

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

EMA wants to embed patient viewpoint within drug assessment

Will pilot CHMP benefit-risk evaluation project

- PMLiVE

Servier abandons cancer drug collaboration with Pharmacyclics

Rights to lymphoma treatment abexinostat will be returned

- PMLiVE

Actelion partners with PatientsLikeMe on blood cancer research

Will create patient-reported outcomes tool for rare form of non-Hodgkin’s lymphoma

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

GSK and Genmab’s Arzerra fails lymphoma trial

Cancer drug unable to beat Roche's MabThera in late-stage study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links